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Mutations in PSEN genes,whichencodepresenilinproteins,causefamilialearly-onsetAlzheimer’sdisease(AD).Transgenicmouse
models based on coexpression of familial AD-associated presenilin and amyloid precursor protein variants successfully mimic
characteristic pathological features of AD, including plaque formation, synaptic dysfunction, and loss of memory. Presenilins
function as the catalytic subunit of γ-secretase, the enzyme that catalyzes intramembraneous proteolysis of amyloid precursor
protein to release β-amyloid peptides. Familial AD-associated mutations in presenilins alter the site of γ-secretase cleavage in
a manner that increases the generation of longer and highly ﬁbrillogenic β-amyloid peptides. In addition to amyloid precursor
protein, γ-secretase catalyzes intramembrane proteolysis of many other substrates known to be important for synaptic function.
This paper focuses on how various animal models have enabled us to elucidate the physiological importance of diverse γ-secretase
substrates, including amyloid precursor protein and discusses their roles in the context of cellular signaling and synaptic function.
1.Introduction
Mutations in PSEN1 and PSEN2 genes, which encode
polytopic proteins termed presenilin 1 (PS1) and presenilin
2 (PS2), respectively, cause autosomal dominant early-onset
familial Alzheimer’s disease (FAD) [1]. Both PS1 and PS2
proteins (PS) share about 63% homology with the highest
similarity in the transmembrane domains where most of
the FAD-linked mutations are found [2, 3]. Since the ﬁrst
report of mutation in the PSEN1 on chromosome 14, about
170 mutations have been identiﬁed, making mutations in
PSEN1 the most common cause of autosomal dominant
early-onset AD [4]. In the case of PSEN2, 18 mutations
have been reported so far, although not all have been
conﬁrmed to be pathogenic [2, 5]. As a probable explanation
for the disparity between the two genes, defects in PSEN2
functionmaybeoﬀsetbythenormalfunctionofitshomolog
PSEN1. In support of this view, PSEN2 null mice do not
exhibit the phenotypic and functional defects seen in mice
lacking PSEN1 gene. PSEN1 knockout (KO) mice are lethal,
and disruption of PSEN2 and PSEN1 genes causes earlier
embryonic lethality compared to PSEN1 KO [6–10]. As
supported by mouse model studies, it appears that PS1
contributes largely to total β-amyloid (Aβ)p r o d u c t i o ni nt h e
brain [11, 12].
PS is the catalytic subunit of γ-secretase, the enzyme
responsible for intramembraneous cleavage of amyloid pre-
cursor protein (APP) to generate peptides. FAD-linked PS
variants enhance the production of highly ﬁbrillogenic Aβ42
peptidesthataredepositedearlyinthebrainsofpatientswith
AD [13]. PS is ubiquitously expressed in the nervous system
and peripheral tissue and found localized in secretory and
endocyticorganellesinallcelltypes,aswellassynapticstruc-
turesinneurons[14,15]. As predicted from its broad pattern
of expression, PS’s function extends far beyond processing of
APP and the pathogenesis of AD. For example, PS’s catalytic
functionisrequiredforintramembraneousγ-secretasecleav-
ageofNotchreceptors,whichreleasestheNotchintracellular2 International Journal of Alzheimer’s Disease
domain (NICD). Nuclear signaling mediated by NICD
is essential during mammalian development; mice with
ablated PSEN1 alleles die in late embryogenesis and exhibit
phenotypes reminiscent of mice lacking Notch 1 [6, 7].
Thus,PS-dependentactivationofNotchsignaling is essential
for early development. Transgenic expression of FAD-linked
mutant PS1 fully rescues the developmental phenotypes in
mice with PSEN1 deﬁciency [16, 17], supporting the notion
that FAD-linked PS1 variants are functional, but acquired
deleteriouspropertiesthathaveprofoundpathophysiological
consequences. Candidate approaches and proteomic studies
have identiﬁed a wide spectrum of type I membrane
proteins that undergo γ-secretase cleavage, including Notch
ligands, Deleted in Colorectal Cancer (DCC), and cadherins
(reviewed in [13, 18–21]). Uniformly these substrates all
undergo an ectodomain shedding by α-secretases, which
in many cases is triggered by the binding of extracellu-
lar ligands. Interestingly, several noncatalytic γ-secretase-
independent functions have been assigned to PS, such
as its role in regulating intracellular calcium homeostasis
(reviewed in [22]).
Synapses are continuously reconﬁgured, both struc-
turally and functionally, during embryonic development and
throughout adult life, forming the basis for learning and
memory [23, 24]. Neuronal inability to exhibit such plastic
changes has been proposed to be a root cause for various
psychiatric and neurodegenerative disorders such as AD
[23, 25, 26]. Not surprisingly, the duration and severity of
cognitive impairments in AD patients closely parallels the
extent of synaptic loss, leading to the notion that synaptic
dysfunction is a critical element in the pathophysiology of
AD [27]. Notably, memory and cognitive decline observed
in AD patients correlate better with the synaptic pathology
thaneitherAβ plaqueloadortangledensity,andsynapseloss
appears to precede neuronal degeneration. Details on how
synaptic organization is altered in AD patients are beginning
to emerge. Findings from several laboratories suggesting that
Aβ might play a critical role in synaptic dysfunction have
added signiﬁcant information to the traditional amyloid
cascade hypothesis of AD [28, 29]. Aβ can aﬀect synaptic
transmission [30–33], synaptic protein localization [34],
AMPA and NMDA receptor traﬃcking [35, 36], and spine
formation [35, 37–39].
FAD-linked mutations in PS1 were originally thought
to enhance the production of Aβ42 peptides by a gain-
of-function mechanism. However, it is becoming clear
that FAD-linked PS1 variants also exhibit partial-loss-of-
enzymatic-function observed as diminution of Aβ40 peptide
production and defects in the extent of processing certain
other transmembrane substrates (reviewed in [40, 41]).
For example, FAD-linked PS1 mutations are thought to
attenuate γ-secretase processing and generate reduced levels
of the intracellular domains of APP, Notch, N-cadherin,
EphB2, and EphA4 [42–45]. Taken together, it is plausible
that FAD-linked mutations in PS1 exert pathophysiological
eﬀects on the synapses by elevating Aβ42 levels and by Aβ-
independent mechanisms involving altered processing of γ-
secretase substrates involved in synaptic function. This paper
discusses ﬁndings from various animal models that reveal
the role of PS and FAD-linked PS mutations in synapse
formation and function.
2. PS AnimalModels
Several mouse models (reviewed in [46]; see http://www
.alzforum.org/res/com/tra/)a n daf e wr a tm o d e l s[ 47–50]
have been developed in order to recapitulate the main
pathological features of AD and elucidate the mechanisms
by which FAD-linked PS mutations contribute to AD patho-
genesis. A variety of mouse models have been characterized
such as mice expressing FAD-linked PS variants harboring
point mutations or deletion mutation [51, 52], and FAD-
linked PSEN1 knock-in (KI) [M146V variant [53], I213T
variant[54]andP264Lvariant[55]],andΔE10loopdeletion
KI [56]. These FAD-PS1 single transgenic or KI mouse
models do not exhibit signiﬁcant Aβ deposition in the
brain.Therefore,thephenotypesdescribedintheseFAD-PS1
single transgenic mice are not due to classical Aβ pathology.
In an attempt to reproduce more closely the human AD
pathology, PSEN1 KI coexpressing APP “Swedish” mutant
and hyperphosphorylated tau mutants have been made [57].
In order to study the physiological function of PS, KO
models of PSEN1 and PSEN2 [6–10], PSEN1 conditional KO
[58–60], as well as double PSEN1 and PSEN2 conditional
KO [61] mice have also been created. In order to examine
amyloid pathology, transgenic mice expressing APP mutants
in a PS null background have been developed; such as PSEN1
conditional KO coexpressing APP V717I variant [60]a n d
APP V717F variant [62]. In these models, Aβ deposition is
attenuated by the lack of PS1 expression and consequent loss
of γ-secretase activity.
Besides their utility in examining proteolytic processing
of APP into Aβ40 and Aβ42 peptides in vivo and phenocopy-
ing pathological hallmarks of AD (amyloid deposition and
tau phosphorylation), these models have been extensively
used to examine changes in synaptic transmission, synaptic
plasticity, and associated signaling. In addition, several
groups have generated Drosophila models (reviewed in
[63]), and Caenorhabditis elegans models (reviewed in [64])
expressing human PS1 or PS2 bearing FAD-linked muta-
tions, in an eﬀort to understand mechanistic contribution of
PS to AD pathology and neuronal dysfunction.
3. PS andCellularSubstratesof Memory
Synaptic transmission and long-term potentiation (LTP)
contribute to several forms of memory storage. Using slice
preparations from transgenic mice, we and others have
demonstrated that expression of FAD-linked PS1 does not
alter basal synaptic transmission, but leads to higher degree
of LTP induction in the hippocampus ( [57, 65–69]r e vi e w e d
in [14]). However, one group has reported impairment of
synaptic transmission associated with an increase of paired-
pulse facilitation, an index of presynaptic release, in neurons
of 6 month-old PSEN1 M146V KI mice [57]. LTP induction
by high-frequency stimulation in hippocampal CA1 area was
also enlarged in this animal model [57]. Interestingly, in
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(a muscarinic agonist) was reduced in CA1 hippocampal
area, suggesting that FAD-linked PS1 variant might interfere
with cholinergic cellular cascades as well [70] .T h eK Im o u s e
models allow us to examine the functional properties of
moleculesassociatedwithpathologywhentheyareexpressed
atendogenouslevelswithoutanyalterationintheirspatialor
temporal pattern of expression. Therefore, KI animal models
give us the opportunity to rule out pathophysiological
consequences (such as protein misfolding) associated with
aberrant overexpression of proteins associated with human
genetic disorders.
Interestingly, it has been described that the lack of
PS function or overexpression of PS1 mutant was also
associated with changes in presynaptic function. We have
observed an increase of spontaneous miniature excitatory
postsynaptic current in cortical neurons isolated from
PSEN1 KO mice [71], while others have reported that
expression of mutant PS1 in cultured hippocampal neurons
depresses synaptic transmission by reducing the number of
synapses [72]. Another group has also observed that PS1
deﬁciency increases synaptic release and aﬀects the number
and docking of synaptic vesicles [69]. It was also shown
that basal transmitter release was increased at the neuro-
muscular junction in Drosophila lacking PS expression [73].
However, even though basal synaptic transmission seems
to be intensiﬁed in this later model, synaptic strength and
plasticity were impaired after posttetanic potentiation [73].
As a likely consequence, associative learning ability was also
impaired. In parallel, it has been reported that LTP induction
declines more rapidly in CA1 hippocampal area of mice
with only one allele of PSEN1 [74]. In agreement with
these observations, it has been recently found that a CA3-
dependent presynaptic form of LTP in the hippocampus was
attenuatedindoublePSEN1andPSEN2conditionalKOmice
[75]. Intriguingly, single PSEN1 conditional KO mice do
not show major changes in brain plasticity, suggesting that
expression of PS2 might be suﬃcient to overcome the 60–
80% loss of PS1 in the forebrain of these animals [59].
What can we learn from these animal models? First
of all, it becomes apparent from these studies that PS
is an essential element for the normal synapse function.
Second, it becomes evident that PS dosage is a critical
component for PS-dependent cellular function(s). Indeed,
PS1 expression is developmentally regulated in rodent brain,
reaching a peak of expression during the critical period
of synaptogenesis between postnatal days 7 to 14 [76].
Accordingly, we can stipulate that PS-dependent substrates
expressed during embryogenesis or early in development
may signiﬁcantly contribute to synaptic physiology. In this
regard, it also remains to be established whether diﬀerences
in PS-dependent proteolysis of developmentally regulated
molecules might underlie changes in synaptic function
later on in life. A well-known example is a condition
where stress-induced early life biochemical events inﬂuence
life-span changes in cognitive function and AD-associated
abnormalities [77]. Accordingly, it has been proposed that
age-related decline in cortical cholinergic function in AD
patients might have developmental origins [78]. Finally, it
has also been speculated that PS-dependent modulation of
signaling pathways that are important in development may
contribute to the neurodegenerative process [79]. Taken
together, studies from various laboratories suggest that PS
is speciﬁcally involved in cellular component(s) necessary
forsynaptic transmission and plasticity, and thatFAD-linked
mutationsinPS1maydisruptthenormalcascadeofsynaptic
events.
4. PS andSynapseFormation
A distinct feature of the nervous system is the intricate net-
work of synaptic connections among neurons. The changes
in the strength and eﬃcacy of existing synapses, as well as
remodeling of connectivity through the loss and gain of
synapses in the neuronal network, are believed to be the
basis of learning and memory in the brain. Interestingly,
LTP has been associated with the increase in spine formation
and spine head growth, whereas long-term depression (LTD)
has been associated with spine shrinkage and retraction
[80]. The morphology of dendritic spines is known to
change in response to several factors including learning, age,
hormones, and disease conditions [81]. In addition to their
morphological plasticity, spine-like protrusions also display
rapidmotility,changingshapeandsizeinamatterofseconds
to minutes. This morphological plasticity suggests that long-
term memory might be encoded by alterations in spiny
structuresand associated synaptic contacts [82]. Collectively,
these events are critically important in synaptogenesis, in
modulating of existing synapses, as well as in long-term
synaptic plasticity [83, 84]. It has been reported that Aβ is
closely associated with a decrease of spine formation and
motility [35, 37, 85]. Overproduction of Aβ in PS mutant
transgenic mice coexpressing the “Swedish” APP mutant
causes age-associated decrease of synaptic excitability [57,
86, 87] and spine collapse [38, 88]. However, it has also
been reported that acute Aβ application (less than 4h) was
associated with an increase of ﬁlopodia and growth cones
in hippocampal cultures [89]. In support of this idea, it
was shown that application of low levels of Aβ is associated
with an increase of LTP, whereas higher concentration of
Aβ reduced synaptic potentiation [32, 90]. Collectively,
these observations suggest that Aβ m i g h th a v ed u a lr o l e s
on synapse formation. Conﬂicting results have also been
observed in regard to spine morphology in neurons lacking
PS expression. Treatment with Compound E, a γ-secretase
inhibitor (10nM; 24h), produced an increase of spine-like
protrusions in isolated neurons [71, 91]; whereas the density
of spines was found to be decreased upon prolonged treat-
ment with the same inhibitor (50nM; seven days) [45]. In
addition, neurons lacking both PS1 and PS2 expression have
marked diminution in spine density [45]. To further support
the eﬀectofγ-secretase inhibition on dendritic spines, recent
in vivo study showed that γ-secretase inhibitor treatment in
wild-type mice signiﬁcantly reduced the number of spine
density in somatosensory cortex, while γ-secretase inhibitor
treated APP null mice did not exhibit any eﬀect [92].
These ﬁndings suggest that APP-dependent mechanism may
underlie the PS-dependentmorphological changes observed.
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loss of PS expression on spine density may be also due
to diﬀerential eﬀects of inhibitors that target mainly γ-
secretase and genetic inactivation of PS that results in
reduced γ-secretase-dependent and -independent function.
All together, these observations support the idea that PS
gene dosage and the level of expression may diﬀerentially
inﬂuence synaptic morphology.
Although the molecular mechanisms that underlie these
morphological changes are not completely understood,
emerging evidence supports at least two important signaling
pathways that have been linked to dendrite spine formation
andADetiology:(1)cAMP-dependentactivationofPKAhas
been shown to be critical for the maintenance of the late
phase of LTP, and downstream phosphorylation of CREB has
been linked to formation of new spines [93]. Interestingly,
it has been shown that Aβ inhibits PKA/CREB pathway
[94], (2) the Rho family of small GTPases, well-known
regulators of the actin cytoskeleton, has profound inﬂuence
on spine formation. Among the members of this family
Rac1, Cdc42, Rnd1, and Ras promote spine formation and
growth, whereas Rap and RhoA induce shrinkage and loss of
spines [80, 95]. p21-activated kinase (PAK) is a downstream
signaling eﬀector of the Rho/Rac family of small GTPases
and has been shown to be associated to spine formation
and memory consolidation [96]. A role of PAK in cognitive
d e ﬁ c i t so fA Dh a sa l s ob e e nr e p o r t e d[ 97].
A recent paper by Shuai and colleagues [98] suggests
that the act of forgetting might also be linked to activation
of the Rac pathway, using a simplistic model of olfactory
learning in the fruit ﬂy Drosophila. With the help of genetic
manipulation, they were able to distinguish changes in Rac
activity during passive memory decay, interference learning,
and reversal learning, which are three diﬀerent forms of
forgetting events. In Drosophila olfactory memory model, it
appears that cAMP/PKA and Rac/PAK-dependent memory
acquisition and forgetting events are independent, as sug-
gested by this group and others [98, 99]. In a more complex
system,asithasbeenproposedinthemammals,itseemsthat
memory consolidation might mechanistically require both
pathways [96, 100, 101]. As demonstrated by several groups,
Rac signaling cascade in the brain is directly linked to an
increase of spine formation through subsequent activation
of PAK leading to F-actin polymerization and changes in
membrane morphology. Besides the known involvement of
cAMP/PKA/CREB activation cascade, Rac/PAK-dependent
cellular events also appear to be intimately associated with
the process of memory consolidation, at least in rodents.
It is very exciting to think that perhaps similar cellular
pathways as the one described above may be relevant to
human disorders associated with memory dysfunction. One
of the known hallmarks of AD is that patients do forget
recent events, therefore, they are unable to consolidate
their new memory. In our lab, we have shown that the
lack of PS function or expression in cortical neurons
produced an increase of steady-state levels of CREB and
Rac/PAK cascade activation, which was also associated with
an increase of spine-like protrusions [91]. Even though our
study shows increase of phosphorylated CREB especially
in dendritic area, transcriptional CREB activity was not
directly determined in this experiment. More recently, Shen
and collaborators have shown that CREB transcription
was indeed reduced in PS deﬁcient neuron through PS-
independent mechanism [102]. Are these signaling events
meaningful in the context of AD? Perhaps. As discussed
above, recent studies support the idea that FAD-linked
mutations in PS1 might cause a partial loss of function
[40, 41]. It still remains to be determined whether Rac/PAK
signaling is altered in neurons expressing FAD-linked PS1
variants. If this is the case, one might want to consider the
possibility that changes in cAMP/PKA/CREB or Rac/PAK
signaling in neurons might represent some of the earliest
cellular dysfunctions that are relevant to synapse elimination
and associated cognitive decline in AD.
5. PS-DependentSubstrateSignaling
γ-secretase-dependentPSfunctionmediatestransmembrane
proteolysis of several substrates including APP, N- and
E-cadherins, γ-protocadherin, CD44, DCC, ephrin/Eph
receptors, leukocyte-common antigen related, nectin-1α,
a n ds y n d e c a n( r e v i e w e di n[ 18, 20, 21]). Many of these
substrates function as cell-adhesion molecules or cell surface
receptors and are known for their diverse functions during
development and are involved in axon guidance, neuronal
outgrowth and synaptogenesis [103–113]. In addition, these
molecules are also well known to be coupled to diverse
intracellular signaling pathways [20, 44, 45, 108–110, 114–
118]. It has been proposed that APP can aﬀect synaptic
function by its dual roles via its cell adhesive properties
or through its putative receptor-like intracellular signaling
components [112, 116, 117]. Indeed, it has been shown
that accumulation of the APP intracellular domain can
mediate a phosphoinositide-dependant calcium signaling
[119]. Several other substrates of γ-secretase are also cou-
pled with intracellular signaling events that can potentially
inﬂuence synaptic function. For example, Eph receptors and
N-cadherin are known to be coupled to Rac and CREB
signaling, respectively [45, 115, 117, 120, 121]. Lack of EphB
expression or kinase-defective EphB is associated with a
reduction in glutamatergic synapses and abnormal spine
development [120–122].
IthasalsobeenshownthatthreesubstratesofPS,namely
ErbB4, γ-protocadherin, and leukocyte-common antigen
related, are associated with PSD-95 clustering at the synapse
[123, 124] and AMPA receptor function [125]. Consistent
with these ﬁndings, we have previously reported that the
lack of PS function increases axodendritic contacts, which
was accompanied by increases of PSD-95 clusters, spine-like
protrusions, and AMPA receptors-mediated synaptic trans-
mission[71,91].Moreover,PS1KOneuronsandWtneurons
treated with γ-secretase inhibitors exhibited increases in
the extent of cAMP/PKA activation [71, 91]. cAMP/PKA
signaling plays a critical role in regulating short and long-
term synaptic physiology [126]. It has been demonstrated
that stimulus-induced activation of PKA pathway can also
aﬀect the synaptic morphology; therefore, it can indirectly
aﬀect basal synaptic transmission [127]. Thus, there exists
a close relationship between increased phosphorylation ofInternational Journal of Alzheimer’s Disease 5
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Figure 1: Schematic representation of PS-dependent processing of substrates and their role in synaptic function. Several γ-secretase
substrates are located at the synapse where they inﬂuence the function of other synaptic proteins. Lack of γ-secretase-dependent cleavage of
substrates could perturb presynaptic release and postsynaptic function of glutamate receptor-mediated events (NMDA-GluN and AMPA-
GluA receptors). Synaptic contact could also be modulated through cell-adhesion properties of several γ-secretase substrates. Ineﬃcient
processing of these substrates will lead to sustained activation of signaling cascades capable of altering the postsynaptic morphology. How
FAD-linked mutations in PS inﬂuence these processes and contribute to the disease progression has not been fully understood.
PKA substrates and enhanced synaptic transmission in
neurons lacking PS function [71, 91].
SignalingdownstreamofDCC,thenetrinreceptor[105],
is also modulated by γ-secretase activity [71]. Upon binding
of the ligand netrin, DCC undergoes metalloprotease-
dependent ectocomain shedding [128], which generates
a membrane-tethered DCC C-terminal fragment (CTF)
derivative, consisting of the transmembrane segment and
the intracellular domain. DCC CTF undergoes intramem-
braneous proteolysis by γ-secretase, and accumulation of
DCC CTF in neuroblastoma cells treated with γ-secretase
inhibitorsstimulatesneuriteoutgrowth[71,129].γ-secretase
processing of DCC attenuates cAMP-dependent signaling
cascades associated with DCC CTF [71]. In this case, it
is clear that γ-secretase terminates intracellular signaling
associated with DCC. However, it remains to be determined
if γ-secretase cleavage of other substrates would signiﬁcantly
impact cellular functions, especially pertaining to synaptic
process, through termination of receptor-mediated signaling
events (see our proposed model in Figure 1).
More recently, it was found that EphA4 undergoes
PS-dependent endoproteolytic process, and EphA4 CTF
accumulates following inhibition of γ-secretase activity or
in cells lacking PS expression [45]. Accumulation of EphA4
CTF was found tightly linked to an increase of spine-like
protrusions in hippocampal cultures. Overexpression of an
inactive Rac form abolished the enhancement of dendritic
spines in neurons and lamellipodia formation in NIH3T3
cell lines. In addition, this study showed that overexpression
of membrane-tethered EphA4 intracellular domain was also
associated with an increase of lamellipodia formation in
NIH3T3 cell lines. All together, these results suggest that
enhanced accumulation of EphA4 intracellular domain may
induce Rac-dependent signaling events that regulate cell
morphology.
It is clear that loss of intramembraneous proteolysis of
γ-secretase substrates leads to the accumulation of their
membrane-tethered cytosolic domains. The CTFs of certain
substrates might serve as membrane anchors to facilitate
the recruitment of signaling proteins in a manner that
enhances phosphorylation of downstream signaling sub-
strates. One of the signalings that have been implicated
with PS function is GSK3β ( r e v i e w e di n[ 130]). It is well
established that PS1 can interact with the GSK3β/β-catenin
complex [131–133]. However, besides this direct physical
interaction with PS1, it is known that GSK3β is a ligand-
receptor signaling molecule downstream of the activation of
phosphatidylinositol-3-kinase pathway (reviewed in [134]).6 International Journal of Alzheimer’s Disease
Speciﬁcally, it has been shown that GSK3β signaling is
important for axon speciﬁcation and elongation during the
establishment of neuronal polarity (review by [135]). In
addition,ithasbeenreportedthatdecreaseofGSK3β activity
parallels LTP induction paradigms, whereas inhibition of
phosphatidylinositol-3-kinase and subsequent activation of
GSK3β lead to decrease of LTP ([136]; reviewed in [130,
137]). Decreased phosphorylation of GSK3β at the Ser 9
residue, indicative of an increase of GSK activity, was also
observed in PS1-deﬁcient neurons as well as in PS1 neurons
carrying FAD-linked mutations [69, 138–141]. Alteration
of phosphatidylinositol-3-kinase /Akt signaling cascade has
been proposed to be the link between GSK3β activity and
PS function [138, 140, 142]. Interestingly, increase of GSK3β
activity also leads to hyperphosphorylation of tau protein,
which underlies one of the known pathological hallmarks of
AD, namely the tangle formation (reviewed in [130]).
It has been proposed that membrane microdomains rich
in cholesterol and sphingolipids, termed lipid rafts, might
inﬂuence γ-secretase activity and processing of substrates
(reviewed in [143]). Lipid rafts play an important role in
the maintenance of synapses through dendritic spine for-
m a t i o na n dA M P Ar e c e p t o rf u n c t i o n[ 144]. Raft-dependent
mechanisms facilitate traﬃcking of receptors in and out
of the synapse and regulate synapse function (reviewed
in [145]). Lipid rafts are known to serve as membrane
platforms that compartmentalize diverse receptor-mediated
signaling. Indeed, it was found that critical regulation of
signaling associated with ErbB4, DCC, and EphA4, three
γ-secretase substrates, involves their recruitment into lipid
raft microdomains [45, 146, 147]. Based on the diﬀerences
in spatiotemporal distribution of γ-secretase complexes and
substrates [148, 149], diﬀerent PS-dependent substrates
might be subjected to diﬀerent level of proteolysis depending
on their membrane microdomain distribution at a given
time during embryonic development and in adult life.
6. PSand CalciumSignaling
Besides a direct interaction of γ-secretase substrates with
intracellular phosphorylation cascades, one of the key fea-
turesofPSfunctionisitsroleinintracellularCa2+ homeosta-
sis (reviewed in [22, 150, 151]). Ca2+ homeostasis is essential
to maintain healthy cellular dynamics leading to proper
physiological functions. Several studies have concluded that
FAD-linked PS mutant expression in transfected cells and
cultured neurons is associated with enhanced Ca2+ release
from endoplasmic reticulum store. It has been reported that
neurons generated from PSEN1 M146V KI mice exhibit
an increase of IP3-evoked Ca2+ responses in brain slices as
early as in one month old [152]. This Ca2+ dysregulation
appears to be speciﬁc to intracellular endoplasmic reticulum
s t o r es i n c ei td o e sn o ta ﬀect the voltage-gated Ca2+ entry.
However, it has been shown that L-type Ca2+ channel may
be involved after stress induction at the neuromuscular
junction in drosophila larvae expressing FAD-linked PS1
mutant [153]. Accordingly, in this model system, the level
of synaptic plasticity and memory paradigm was normal
following heat shock stimulation or endoplasmic reticulum
stress, but reduced after 24h of stimulation recovery. These
results suggest that mutation in PS might alter synaptic
behavior following recovery of stress conditions. It has been
also proposed that PS might serve as a passive Ca2+ leak
channel in the endoplasmic reticulum and FAD-linked PS
variants might fail to exhibit this property [154]. Using
reconstituted planar lipid bilayers, Tu and collaborators
demonstrated that PS by itself could form low-conductance
divalent ion channels, which was not the case in several
mutated forms of PS. It remains to be determined if results
from these experimental conditions are applicable to in vivo
situations that are relevant to the disease state.
More recently, Stutzmann and collaborators have estab-
lished that the ryanodine receptor-evoked Ca2+ release
(especially through RyR2 isoform) was increased in CA1
hippocampal slices of PSEN1 M146V KI mice coexpressing
Swedish APP and hyperphosphorylated tau mutants [155].
As a consequence, they observed an aberrant increase of
ryanodine-dependent presynaptic neurotransmission, along
with increases of long-term synaptic plasticity. Conversely,
Shen and collaborators have observed a decrease of
ryanodine-dependent presynaptic release in hippocampal
neurons of PS-deﬁcient mice [75]. All together, Stutzmann
group concluded from their study that signiﬁcant Ca2+
alterations are present at an early age even though Ca2+
homeostasisappearstobemaintained.Compensatorymech-
anisms seem likely to take place in order to maintain normal
synaptic function in early age. However, these subtle Ca2+-
mediated alterations may have profound impact later on that
can aﬀect synaptic and cognitive functions in disease states.
7. Conclusions
Production and deposition of Aβ peptides clearly have
central role in AD pathogenesis. However, it is becoming
clear that FAD-linked mutations in PS proteins aﬀect diverse
physiological processes in addition to promoting the pro-
duction of highly ﬁbrillogenic Aβ42 peptides. The identiﬁ-
cation and characterization of γ-secretase substrates and the
mechanistic details on the successive cleavage of substrates
by the γ-secretase have enhanced our understanding of
how partial loss-of-function associated with FAD-linked PS
mutationscaninfactleadtoagainofactivitieswithreference
to intracellular signaling associated with certain substrates
such as DCC, ErbB4, and EphA4. At least in some cases,
lack of γ-secretase processing leads to profound changes
in synaptic structure and functions as a consequence of
sustained intracellular signaling by substrateCTFs. As details
begin to emerge on additional γ-secretase substrates, it will
be possible to determine whether γ-secretase cleavage of
neuronalreceptors isindeed a regulatorystepthatmodulates
physiological signaling downstream of ligand binding and
ectodomain shedding. Still, the major task is to establish
whether or not altered signaling directly contributes to AD
pathogenesis and/or AD-related synaptic dysfunction.
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